Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is an oral P2Y12 platelet inhibitor used to reduce the risk of thrombotic cardiovascular events. It is a direct-acting, reversible antagonist.
## Primary Indications
* Reduction of thrombotic cardiovascular events (e.g., myocardial infarction, stroke) in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI) who are treated with aspirin.
## Adult Dosing
* **ACS:** Loading dose of 180 mg orally once, followed by 90 mg orally twice daily.
* **Post-MI (at least 1 year after ACS or with risk factors):** 60 mg orally twice daily.
* **Duration of therapy:** Typically 12 months in ACS, but may be extended based on individual risk assessment. For post-MI patients, therapy duration is not well established beyond 1 year.
## Pediatric Dosing
* Dosing for pediatric patients is not established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is recommended for mild to severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is recommended for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
## Contraindications
* Active pathological bleeding (e.g., intracranial hemorrhage, active gastrointestinal bleeding).
* History of transient ischemic attack (TIA) or stroke.
* Concomitant use of strong CYP3A4 inhibitors.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Most common:** Bleeding (including fatal and serious bleeding), dyspnea, bradyarrhythmia.
* **Other:** Ventricular pauses, hyperkalemia, increased serum creatinine.
## Key Drug Interactions
* **CYP3A4 Substrates (especially strong inhibitors):** Ticagrelor is a moderate inhibitor of CYP3A4. Avoid concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, ritonavir).
* **CYP3A4 Substrates (especially statins):** Ticagrelor can increase plasma concentrations of statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin). Use caution and consider lower statin doses.
* **CYP2C19 Substrates:** Ticagrelor is a moderate inhibitor of CYP2C19, which can affect clopidogrel metabolism. Avoid coadministration with clopidogrel.
* **Aspirin:** Concomitant use increases bleeding risk.
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Concomitant use increases bleeding risk.
* **Non-steroidal anti-inflammatory drugs (NSAIDs):** Increased risk of gastrointestinal bleeding.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Renal function:** Monitor serum creatinine.
* **Electrolytes:** Monitor potassium levels, especially in patients with risk factors for hyperkalemia.
* **ECG:** Monitor for bradyarrhythmias.
## Clinical Pearls
* Ticagrelor should be taken for the duration recommended by the treating physician, typically 12 months for ACS patients.
* Discontinuation before the recommended duration can increase the risk of thrombotic events.
* Patients experiencing dyspnea should be evaluated for underlying causes, but if no other cause is found, ticagrelor may be continued if benefits outweigh risks.
* Dose of aspirin should be maintained at 75-100 mg once daily in ACS patients.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and your healthcare provider for diagnosis and treatment. Dosing and recommendations may vary based on individual patient factors and local protocols.*
